Sun Pharma has reported a 49% growth in net profits in the third quarter of the current year on the back of a 41% growth in the topline. Formulations, which account for 66% of the company’s turnover grew by 39% in the third quarter while bulk drugs grew by 43%. Sun Pharmaceuticals manufactures formulations in niche segments such as psychiatry, cardiovascular, gastroentology and neurology. The company has also managed to improve its margins in the third quarter by 190 basis points despite the fact that Gujarat Lyka (which produces bulk drugs) has been amalgamated with Sun Pharma in the current year.
(Rs m) | 3QFY00 | 3QFY01 | Change |
Sales | 1,124 | 1,578 | 40.4% |
Other Income | 16 | 14 | -10.1% |
Expenditure | 865 | 1,185 | 36.9% |
Operating Profit (EBDIT) | 259 | 393 | 52.0% |
Operating Profit Margin (%) | 23.0% | 24.9% | |
Net Interest | - | - | |
Depreciation | 30 | 40 | 31.4% |
Profit before Tax | 244 | 368 | 50.6% |
Other Adjustments | - | ||
Tax | 15 | 27 | 83.9% |
Profit after Tax/(Loss) | 229 | 340 | 48.4% |
Net profit margin (%) | 20.4% | 21.6% | |
Earnings per share* | 19.63 | 29.13 |
What is encouraging for the company is the continuous growth in formulation exports, which have almost quadrupled in the third quarter. A primary reason for the stupendous growth is the amalgamation of Sun Pharmaceutical Exports during the quarter.
Also, Sun has been extremely aggressive in the launch of new products in the domestic market with 24 new product launches in the first nine months of the current year which has helped it maintain its dominance in the cardiovascular, diabetes and central nervous system.
Perhaps the only area of concern is the continuing losses of its US based affiliate Caraco Pharma, which is the company’s vehicle for launch of generics. (Sun has invested Rs 288.63 m towards equity and Rs 252.86 m towards debt in Caraco, which is expected to register a loss of around $ 6 m for the year ended December 2000, although it has not announced the same.) Caraco has submitted around nine abbreviated new drug applications (ANDA) which are awaiting US FDA approval and only after their approvals can revenues start to flow in. Sun has however not provided for this diminution in the value of its investments in its books.
The stock quotes at Rs 560 which implies an earnings multiple of 19.2 times FY01 annualised earnings.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
Equitymaster requests your view! Post a comment on "Impressive results from Sun Pharma". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!